Research location
Redlands
California, United States
Advertisement
Research activity in Redlands
California, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 154 trials and 156 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Redlands
154 linked trials · page 1 of 4Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaNCT07686263 · 2026-08-20 · 1 site observation
RECRUITING
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using SolriamfetolNCT07484217 · 2026-02-23 · 1 site observation
RECRUITING
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderNCT07115329 · 2026-01-05 · 1 site observation
RECRUITING
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorNCT07105111 · 2025-08-29 · 1 site observation
RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)NCT07033494 · 2025-07-16 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseNCT06976216 · 2025-07-14 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240 · 2025-06-19 · 1 site observation
RECRUITING
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06911112 · 2025-03-31 · 1 site observation
RECRUITING
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044 · 2025-03-03 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · 2024-11-18 · 1 site observation
RECRUITING
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsNCT06559306 · 2024-07-25 · 1 site observation
RECRUITING
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric PatientsNCT06372964 · 2024-05-14 · 1 site observation
RECRUITING
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsNCT06228326 · 2024-04-17 · 1 site observation
RECRUITING
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderNCT06229210 · 2024-01-25 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive SymptomsNCT06223880 · 2023-12-27 · 1 site observation
RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18 · 1 site observation
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation
RECRUITING
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive DisorderNCT06785012 · 2024-12-26 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)NCT06721156 · 2024-12-16 · 1 site observation
TERMINATED
Ocular Safety and Usability Study for FYB203 PFSNCT06708637 · 2024-09-20 · 1 site observation
COMPLETED
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and PleasureNCT06635135 · 2024-09-19 · 1 site observation
TERMINATED
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)NCT06423781 · 2024-08-01 · 1 site observation
COMPLETED
Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionNCT06419608 · 2024-05-28 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)NCT06270836 · 2024-05-01 · 1 site observation
COMPLETED
New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)NCT06357832 · 2024-04-29 · 1 site observation
COMPLETED
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolNCT06360419 · 2024-03-18 · 1 site observation
COMPLETED
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDDNCT06011577 · 2023-08-17 · 1 site observation
TERMINATED
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung CancerNCT05800015 · 2023-08-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT05785767 · 2023-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsNCT05671510 · 2023-06-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 · 2022-12-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT05619692 · 2022-11-29 · 1 site observation
COMPLETED
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15NCT05546476 · 2022-11-21 · 1 site observation
COMPLETED
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive DisorderNCT05593029 · 2022-11-09 · 1 site observation
COMPLETED
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive DisorderNCT05536414 · 2022-09-12 · 1 site observation
COMPLETED
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)NCT05463731 · 2022-08-01 · 1 site observation
COMPLETED
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous PatientsNCT05397600 · 2022-06-22 · 1 site observation
COMPLETED
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseaseNCT05310071 · 2022-06-02 · 1 site observation
TERMINATED
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerNCT05353257 · 2022-05-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)NCT05335122 · 2022-03-16 · 1 site observation
COMPLETED
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT05061719 · 2021-10-08 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)NCT05066230 · 2021-09-07 · 1 site observation
TERMINATED
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)NCT05026866 · 2021-08-27 · 2 site observations
ACTIVE_NOT_RECRUITING
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT04985942 · 2021-07-30 · 1 site observation
COMPLETED
A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive DisorderNCT04969510 · 2021-06-24 · 1 site observation
COMPLETED
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)NCT04740918 · 2021-06-07 · 1 site observation
TERMINATED
Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology TreatmentNCT04862195 · 2021-05-15 · 1 site observation
TERMINATED
A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785 · 2021-05-13 · 1 site observation
COMPLETED
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)NCT04855747 · 2021-03-30 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.